Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis

Mostafa, Badr Eldin; Fadel, Michael G; Mohammed, Mohammed Amir; Hamdi, Tarek Abdel Hamid; Askoura, Anas

doi:10.1007/s00405-019-05650-y

Cited by 17 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this review, we identified 9 studies that met our criteria of having a biologic intervention with an active comparator group: omalizumab; 58,1174,1642,1643 dupilumab; 56,60 mepolizumab; 57,1644 and reslizumab 59 . No studies were identified for benralizumab.…”

Section: Chronic Rhinosinusitis With Nasal Polyps (Crswnp)mentioning

confidence: 99%

“…Bidder et al reported a small case‐control study suggesting patients taking omalizumab have improved patient‐reported outcome scores 1642 . Mostafa et al performed a single‐blinded and small study in patients with CRSwNP (AFRS subtype) and reported that patients taking omalizumab have improved patient‐reported outcome scores 1643 . Hayashi et al used omalizumab in 21 patients with CRSwNP and AERD.…”

Section: Chronic Rhinosinusitis With Nasal Polyps (Crswnp)mentioning

confidence: 99%

“…Therefore, it is difficult to make any treatment conclusions. Mostafa et al 1643 performed a prospective single‐blind RCT examining 20 patients with AFRS. Patients received 1 dose of omalizumab 150 mg 2 weeks postoperatively or twice daily topical nasal steroids for 6 months.…”

Section: Chronic Rhinosinusitis With Nasal Polyps (Crswnp)mentioning

confidence: 99%

See 2 more Smart Citations

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

518

479

View full text Add to dashboard Cite

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.

show abstract

Section: Chronic Rhinosinusitis With Nasal Polyps (Crswnp)mentioning

confidence: 99%

Section: Chronic Rhinosinusitis With Nasal Polyps (Crswnp)mentioning

confidence: 99%

See 1 more Smart Citation

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

518

479

View full text Add to dashboard Cite

show abstract

“…We attempted to contact the author through multiple modalities (phone, e-mail, conference website) with no response, and the drug maker could not confirm that such a trial was completed. The third trial 33 was excluded because it reported a combined effect of surgery and mAb therapy where the individual effects could not be isolated. We contacted the author for clarification, with no response.…”

Section: Resultsmentioning

confidence: 99%

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis

Oykhman

Paramo

Bousquet

et al. 2022

Journal of Allergy and Clinical Immunology

147

View full text Add to dashboard Cite

Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory condition of the upper airways. Optimal management is unclear. Objective: We compared the effects of mAbs and aspirin desensitization (ASA-D) for treatment of CRSwNP. Methods: We searched the Medline, Embase, Cochrane Central Register of Controlled Trials, International Clinical Trials Registry Platform, US Food and Drug Administration, and the European Medicines Agency databases from inception to August 4, 2021, for randomized controlled trials comparing the effects of mAbs and ASA-D for CRSwNP. We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events. We used the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach to assess certainty of evidence. PROSPERO CRD42020177334. Results: Twenty-nine randomized controlled trials evaluating 8 treatments (n 5 3461) were included in the network metaanalysis. Compared to placebo, moderate to high certainty evidence showed that health-related quality of life (SNOT-22) improved with dupilumab (mean difference [MD] 219.91 [95%

show abstract

“…While other studies have also reported positive results for omalizumab in terms of clinical symptom improvements, most of them examined a small number of patients with CRSwNP and failed to systematically analyze their results. [37][38][39][40][41] Furthermore, there is still a lack of studies investigating the changes in biomarkers following the administration of omalizumab.…”

Section: Dupilumab (Dupixent ® )mentioning

confidence: 99%

Practical Review of Biologics in Chronic Rhinosinusitis With Nasal Polyps

et al. 2021

View full text Add to dashboard Cite

Well-characterized in chronic rhinosinusitis, type 2 inflammation is frequently associated with nasal polyps, comorbid asthma, and nonsteroidal anti-inflammatory drug hypersensitivity. Despite medical and surgical treatment, it recurs in a significant proportion of patients. Thus, severe uncontrolled type 2 chronic rhinosinusitis with nasal polyps is the most difficult-to-treat phenotype of chronic rhinosinusitis. Recently, dupilumab, a monoclonal antibody against IL-4 receptor α, and omalizumab, a monoclonal antibody against immunoglobulin E, were approved for patients with chronic rhinosinusitis with nasal polyps in the United States, Europe, and Korea. Therefore, rhinologists should understand novel biologics and their use. Here, we provide a literature review of several biologics with their indications, effectiveness, and safety.

show abstract

Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis

Cited by 17 publications

References 33 publications

International consensus statement on allergy and rhinology: rhinosinusitis 2021

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis

Practical Review of Biologics in Chronic Rhinosinusitis With Nasal Polyps

Contact Info

Product

Resources

About